1. Introduction {#sec1-ijms-17-01845}
===============

The continuous search for tumor markers has yielded several positive results \[[@B1-ijms-17-01845]\]. Research on biomarkers playing a vital role in the early diagnosis and individualized treatments of the tumors is rapidly advancing as we begin to understand the complex mechanisms during tumor carcinogenesis and progression \[[@B1-ijms-17-01845]\]. The identification of molecular subtypes of non-small cell lung carcinoma (NSCLC) has transformed the clinical management of this disease, which is best exemplified by the clinical success of targeting the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKI) as the first line of treatment \[[@B2-ijms-17-01845]\]. However, lung cancer is still the leading cause of cancer mortality worldwide. The high mortality is due to the poor prognosis of the disease caused by late presentation of illness, tumor heterogeneities within histological subtypes, and the limited understanding of tumor biology. Importantly, difficulty in early diagnosis of lung cancer is due to the lack of a quintessential biomarker \[[@B3-ijms-17-01845]\]. Recently, invasive biomarkers present in sputum, plasma, serum, or whole blood have increasingly been explored for the early diagnosis of NSCLC.

The practice of liquid biopsy as a diagnostic, prognostic, and theranostic tool in NSCLC patients is an appealing approach since it is noninvasive and easily reproducible. In particular, this method for the potential detection of circulating biomarkers allows patient monitoring during treatment, as well as the detection of different genomic alterations that may be accessible to targeted therapy or are associated with treatment resistance \[[@B4-ijms-17-01845]\]. Recently, detection and molecular characterization of circulating tumor cells (CTCs) are some of the most active areas in translational cancer research; the use of CTCs as a liquid biopsy may aid in obtaining genetic follow-up data, which is an urgent prerequisite \[[@B5-ijms-17-01845]\]. However, the challenge in the detection of CTCs is the requirement of high sensitivity combined with high specificity \[[@B5-ijms-17-01845]\]. The high heterogeneity and low occurrence frequencies of CTCs which have been detected for a low concentration of 1--10 CTCs/mL in whole blood of patients with metastasis, hinder the development of clinical applications \[[@B4-ijms-17-01845],[@B6-ijms-17-01845]\].

Methods for CTC detection have recently been developed, including CTC microchips, filtration devices, quantitative reverse-transcription PCR assays, and automated microscopy systems \[[@B4-ijms-17-01845],[@B7-ijms-17-01845]\]. A successful detection of rare CTCs in peripheral blood can be achieved by coupling pre-analytical enrichment with molecular detection of enriched cells by reverse-transcription-PCR (RT-PCR) \[[@B8-ijms-17-01845]\]. CTC detection by a panel of markers that show increased expression in tumor cells as compared to the normal epithelial cells is a critical supplement to the current tumor-node-metastasis (TNM) staging system for improved prognosis and rapid assessment of the therapeutic response. These improvements facilitate the design of enhanced therapeutic strategies for the treatment of any solid epithelial cancer \[[@B9-ijms-17-01845],[@B10-ijms-17-01845]\]. Although many promising CTC detection techniques have been developed in recent years, the analytical specificity and specificity of these methods require substantiation in large prospective multicenter studies before clinical utility. In addition, the cost-efficiency of the detection method should also be considered.

Herein, immunobead RT-PCR was developed for the detection of CTCs originating from NSCLC. The technique combined pre-analytical enrichment by density gradient centrifugation (Ficoll-Hypaque separation), immunomagnetic, and size filtration procedures with subsequent RT-PCR detection of a panel of four markers. The markers used for RT-PCR included *CK7*, *ELF3*, *EGFR*, and *EphB4*, which were selected based on the expression in epithelial cancers including NSCLC, as described previously \[[@B11-ijms-17-01845],[@B12-ijms-17-01845],[@B13-ijms-17-01845],[@B14-ijms-17-01845]\]. These markers can be used for the identification of circulating breast cancer cells \[[@B12-ijms-17-01845]\], and cannot be detected in mononuclear cells from peripheral blood samples in normal individuals \[[@B12-ijms-17-01845]\]. Therefore, these markers are specific for the detection of circulating epithelial cells.

2. Results {#sec2-ijms-17-01845}
==========

2.1. Expression Level of CK7, ELF3, EGFR, and EphB4 mRNA in NSCLC Tissues {#sec2dot1-ijms-17-01845}
-------------------------------------------------------------------------

The mRNA level of *CK7*, *ELF3*, *EGFR*, and *EphB4* in NSCLC tissues was significantly higher than that in para-cancerous histological normal tissues (PCHNTs) (all *p* \< 0.0001, respectively, [Figure 1](#ijms-17-01845-f001){ref-type="fig"}A). The average increase of mRNA of *CK7*, *ELF3*, *EGFR*, and *EphB4* was 36.118-, 35.476-, 34.541-, and 32.308-fold, respectively. Successively, the correlation between the four mRNA levels and the clinicopathological characteristics was analyzed ([Table 1](#ijms-17-01845-t001){ref-type="table"}). The results indicated that the expression level of the four mRNAs was closely correlated with the clinical stage, respectively (all *p* \< 0.0001). However, no correlation could be established between the levels of the four mRNAs and age, sex, and smoking history, respectively (all *p* \> 0.05, [Table 1](#ijms-17-01845-t001){ref-type="table"}).

2.2. The mRNA Expression of Selected Markers in Paired PBMC Preparations {#sec2dot2-ijms-17-01845}
------------------------------------------------------------------------

346 blood samples were taken from the recruited participants including 111 NSCLC patients, 115 benign pulmonary disease patients, and 120 healthy controls. No significant difference was observed in the age and gender among the different groups *(p* \> 0.05 for both).

The expression of the four putative markers identified in paired PBMCs was validated by real-time RT-PCR. We found that these four mRNAs were detectable in the majority of PBMC samples from 111 NSCLC patients. Four markers (*CK7*, *ELF3*, *EGFR*, and *EphB4*) were significantly elevated in PBMCs (all *p* ˂ 0.0001) ([Figure 1](#ijms-17-01845-f001){ref-type="fig"}B). However, no significant difference was observed in the expression of the four genes in PBMCs from 115 benign pulmonary disease patients as compared to 120 healthy controls (*p* \> 0.05). Furthermore, the results indicated that these four mRNA levels in PBMCs was closely correlated with the clinical stage (*p* = 0.006, 0.003, 9.62 × 10^−5^, and 0.006, respectively) in NSCLC patients ([Table 2](#ijms-17-01845-t002){ref-type="table"}). The circulating *CK7* mRNA was closely correlated with the patient's age revealed during the first examination (*p* = 0.038). The circulating *EphB4* mRNA was closely correlated with the histopathological type (*p* = 0.032) while the circulating *EGFR* mRNA was closely correlated with the lymph node metastasis (*p* = 0.023) ([Table 2](#ijms-17-01845-t002){ref-type="table"}).

2.3. Receiver Operating Characteristics (ROC) Curve Analysis of the Four mRNAs as a Marker of CTCs {#sec2dot3-ijms-17-01845}
--------------------------------------------------------------------------------------------------

The areas under the ROC curves were 0.909 (0.853--0.965, 95.0% confidence interval (CI)) for *CK7*, 0.917 (0.863--0.971, 95.0% CI) for *ELF3*, 0.939 (0.893--0.986, 95.0% CI) for *EGFR*, and 0.894 (0.834--0.954, 95.0% CI) for *EphB4* ([Figure 2](#ijms-17-01845-f002){ref-type="fig"}). The cut-off values of *CK7*, *ELF3*, *EGFR*, and *EphB4* were defined as a 2-fold increase of the expression compared with the positive control. The sensitivity of each marker was: *CK7* (81.8%), *ELF3* (83.3%), *EGFR* (87.8%), *EphB4* (78.8%), whereas the specificity was: *CK7* (100%), *ELF3* (100%), *EGFR* (100%), and *EphB4* (100%). The expression of at least one of these four markers (a combination of the four markers) was considered as CTC positive. Thus, we determined the effect of the combination of the four markers by constructing a ROC curve and fitting a logistic model with parameters for *CK7*, *ELF3*, *EGFR* and, *EphB4*. The area under the ROC curve was 0.848 (0.779--0.917, 95.0% CI); the sensitivity and specificity were 69.7% and 100%, respectively, when the optimal threshold was defined as a 2-fold increase of expression ([Figure 2](#ijms-17-01845-f002){ref-type="fig"}). These results indicated that the detection of CTCs using the combination of four markers was not superior to the four markers individually.

2.4. Cell-Free RNA Content in Peripheral Blood Is Closely Associated with the Prognosis of NSCLC Patients {#sec2dot4-ijms-17-01845}
---------------------------------------------------------------------------------------------------------

Next, we investigated the association of circulating *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNA with patients' survival. In both disease-free survival (DFS) and overall survival (OS) situations, the four circulating mRNAs were significantly associated with poor prognosis, short DFS, and low OS, respectively. The average durations of DFS and OS in patients with high level circulating *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNAs (tumor PBMCs vs. positive control: \>2-fold) were significantly shorter than those of patients with normal or downregulation of the four mRNAs in the PBMCs ([Figure 3](#ijms-17-01845-f003){ref-type="fig"}). The average DFS in patients with high level circulating *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNAs was 17.6, 17.9, 18.4, and 17.7 months vs. 24.3, 24.2, 24.0, and 24.1 months in patients with a normal or low level of the four mRNAs, respectively. The average OS in patients with high level circulating *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNA was 22.7, 22.9, 23.1, 22.6 months vs. 24.3, 24.2, 24.0, and 24.4 months in patients with a normal or low level of the four mRNAs, respectively ([Table 3](#ijms-17-01845-t003){ref-type="table"}). All of the four circulating mRNAs, including *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNA, were strongly associated with NSCLC patients' prognosis; however, the association of the cell-free RNA content with patient survival was independent of the tumor stage ([Figure 3](#ijms-17-01845-f003){ref-type="fig"}). In addition to the four circulating mRNAs, we observed that a number of other previously characterized clinical parameters were associated with patient survival ([Table 3](#ijms-17-01845-t003){ref-type="table"}), including gender, smoking, and TNM stage. However, no significant correlation was found between a majority of the clinical characteristics such as age at diagnosis, lesion site, histopathological type, tumor size, differentiation, invasive depth, nodal metastasis, and distant metastasis with the patients' prognosis. In summary, these data indicate that in addition to a minority of clinical characteristics that have been shown to affect the prognosis of NSCLC patients, these four circulating mRNAs might serve as a biomarker to predict the DFS and OS of the patients.

3. Discussion {#sec3-ijms-17-01845}
=============

Metastasis is a multistep event. Some tumor cells acquire metastasis ability independent of the in situ tumor and then migrate or invade into the blood and lymph vessels to act as circulating tumor cells \[[@B15-ijms-17-01845]\]. More than 90% of the tumor-related deaths arise out of the progression of hematogenously disseminated metastasis \[[@B16-ijms-17-01845]\]. CTCs play a vital role in metastasis, and detection of CTCs can contribute towards the evaluation of progression, prognosis, and personal treatment \[[@B4-ijms-17-01845],[@B5-ijms-17-01845]\]. However, because of low quantity and heterogeneity of CTCS, a unified detection method to count and classify CTCs has not yet been described \[[@B5-ijms-17-01845],[@B6-ijms-17-01845]\]. Herein, we collected PBMCs from 111 NSCLC patients to detect the target genes' expression originating from epithelium instead of acquiring and examining the CTCs. The elevated levels of gene expression from epithelial origin indicate the existence of CTCs or circulating tumor nuclei in peripheral blood; these cannot be detected in the normal peripheral blood \[[@B17-ijms-17-01845],[@B18-ijms-17-01845]\]. Lung cancer is a heterogeneous disease with respect to histological and biological characteristics \[[@B19-ijms-17-01845]\]. Owing to the heterogeneity of the tumor cells and the limited reliability of single marker, we selected four genes of epithelial origin, described previously, for the analysis of gene expression \[[@B17-ijms-17-01845],[@B18-ijms-17-01845]\]. These four markers cannot be detected in normal mononuclear cells by optimized experiments and are specific for the detection of circulating epithelial cells \[[@B12-ijms-17-01845]\]. The analysis of *CK7*, *ELF3*, *EGFR*, and *EphB4* mRNAs in PBMCs for the detection of CTCs have been reported in various epithelial cancers including NSCLC \[[@B11-ijms-17-01845],[@B12-ijms-17-01845],[@B13-ijms-17-01845],[@B14-ijms-17-01845]\], respectively; however, a combined of these four markers in NSCLC has not yet been reported.

*CK7*, a star member in lung cancer, has been reported in primary or metastatic lung cancer, cavity liquid, and pleural mesothelioma. The frequency of *CK7* upregulation in adenocarcinoma (ADC) was higher than that in squamous cell carcinoma (SCC); it can be used as a potential marker to distinguish the two histological types \[[@B19-ijms-17-01845],[@B20-ijms-17-01845]\]. However, our results were inconsistent with the previous reports. We found that neither *CK7* expression in tissues nor peripheral mononuclear cells was associated with histological types (all *p* \> 0.05). *CK7* mRNA was up-regulated in all 111 NSCLC patients, including 65 ADC and 46 SCC patients. The *CK7* level in both tissues (*p* ˂ 0.0001) and PBMCs (*p* = 0.006) was significantly correlated with the clinical stage. Moreover, circulating *CK7* mRNA was significantly correlated with age during diagnosis (*p* = 0.038). NSCLC patients with low *CK7* expression (fold \< 2) have a long DFS while 92.5% (49/53) patients with high *CK7* expression (fold ≥ 2) suffer progression, metastasis, or death. Therefore, *CK7* overexpression in peripheral cells may be a good biomarker for predicting poor prognosis in NSCLC. *CK7* is almost exclusively expressed in epithelial tissues, especially lung tissues. The expression of *CK7* in lung cancer tissues is elevated and can be used to distinguish between primary lung cancer and lung metastasis of other cancers \[[@B21-ijms-17-01845],[@B22-ijms-17-01845],[@B23-ijms-17-01845]\].

*ELF3* is limited to cells of epithelial origin and is firstly found in lung tissues. Moreover, ELF3 is a transcriptional factor in the ETS-domain family and is known to regulate the expression of several growth-related genes, including angiopoietin 1, collagenase, as well as other transformed growth and invasion-related genes \[[@B24-ijms-17-01845],[@B25-ijms-17-01845]\]. *ELF3* may play a crucial role in lung tumorigenesis and progression. However, the additional functions of *ELF3* in various kinds of tumors have frequently been studied for many years since its expression in lung cancer tissues and lung cancer cell lines was first discovered in 1997 \[[@B25-ijms-17-01845]\]. *ELF3* was demonstrated to possess dual functions in the transcriptional regulation of genes involved in squamous epithelial differentiation. ELF3 suppresses the basal keratin4 promoter activity while simultaneously activating the late differentiation linked small proline-rich protein 2A (*SPRR2A*) promoter in both esophageal and cervical epithelial cancer cell lines \[[@B26-ijms-17-01845]\]. Nakarai et al. evaluated the mRNA expression of *ELF3* and carcinoembryonic antigen (*CEA*) in the lymph node and the tissue from patients with colorectal cancer (CRC) and controls. The results showed that *ELF3* may sufficiently assess the lymph node metastases of CRC \[[@B27-ijms-17-01845]\]. In addition, *ELF3* expression plays a critical role in lung tumorigenesis and is regulated by oncogenic protein kinase C (*PKC*) \[[@B28-ijms-17-01845]\]. Our data indicate that *ELF3* expression in NSCLC tissues is associated with lymph node metastasis and clinical stage; however, its expression in PBMCs is not correlated with lymph node metastasis. Moreover, the increased *ELF3* expression correlated with poor prognosis. Hitherto, there is no report describing the association of *ELF3* expression and metastasis of lung cancer. Hence, these results should be verified by a large sample analysis in the future studies.

*EGFR* is a biomarker used for the prediction of chemotherapy and targeted treatment. It is a representative marker and abnormal expression of *EGFR* influences the treatment and prognosis of lung cancer. When patients with lung cancer carry activating *EGFR* mutations, their first-line of treatment can be selected with EGFR-TKI, like gefitinib \[[@B29-ijms-17-01845]\]. The prognosis of NSCLC patients with mutated *EGFR* was superior to that of the wild-type *EGFR* in NSCLC \[[@B30-ijms-17-01845]\]. We found that high *EGFR* expression level was associated with short DFS and is an independent influencing factor for the prognosis in NSCLC (*p* ˂ 0.0001). Also, it has been demonstrated that patients showed higher *EGFR* expression in SCC than non-SCC (*p* \< 0.05) \[[@B31-ijms-17-01845]\], and co-expression with insulin-like growth factor 1 receptor (*IGF1R*) was associated with poor survival. We found the *EGFR* expression did not correlate with the histological type (*p* \> 0.05).

*EphB4* plays a key role in numerous kinds of tumor, including lung cancer \[[@B32-ijms-17-01845]\], esophageal cancer \[[@B33-ijms-17-01845]\], pancreatic cancer \[[@B34-ijms-17-01845]\], and gliomas \[[@B35-ijms-17-01845]\]. As a member of receptor tyrosine kinases, *EphB4* is frequently implicated in tumor pathogenesis. Moreover, the inhibition of some tyrosine kinases targets EphB4, and is deemed efficient treatment Ferguson et al. \[[@B36-ijms-17-01845]\] found that *EphB4* overexpression promotes cellular proliferation, colony formation, and motility while *EphB4* inhibition reduces cell viability in vitro. The growth of the established tumors in mouse xenograft models can be halted by single-target strategy, and EphB4 may be a potential novel therapeutic target in lung cancer. *EphB4* expression in tumors was increased significantly compared to the control (adjacent normal tissues), which was correlated with differentiation, lymph node metastasis, and TNM stage \[[@B32-ijms-17-01845]\]. However, we found that *EphB4* expression in PBMCs was not associated with the differentiation and lymph node metastasis, but correlated with the histological type and TNM stage. The survival curve of EphB4 was different from the other three genes. The patients with low *EphB4* expression also underwent progression, metastasis, or death.

4. Material and Methods {#sec4-ijms-17-01845}
=======================

4.1. Patients {#sec4dot1-ijms-17-01845}
-------------

A total of 111 NSCLC patients who underwent curative surgery, without prior treatments, at Zhejiang Cancer Hospital (Hangzhou, China) from January 2010 to December 2011, were enrolled in this study. All the patients showed no history of other tumors by examination of a plain chest radiograph, CT scan, fiber optic bronchoscopy, and bone scan and were diagnosed with NSCLC by histopathology. The patients' medical records were reviewed to obtain data including age at diagnosis, sex, and smoking history ([Table 1](#ijms-17-01845-t001){ref-type="table"}). Tumor stage was determined according to the American Joint Committee on Cancer (AJCC)/ Union for International Cancer Control (UICC) TNM tumor classification \[[@B37-ijms-17-01845]\]. The mean age of the patients at tumor resection was 62 years (range 44--82 years); 79 (71.2%) were males and 32 (28.8%) were females. The tumor specimens and paired PCHNTs were collected at the time of surgery. The paired PCHNTs were obtained from the proximity of 5 cm from the tumor edge and was assessed microscopically for the presence of healthy cells and absence of dysplastic cells. The paired peripheral blood samples were collected from these patients during diagnosis before surgery, radiation, or chemotherapy. The tissue and blood specimens for the present study were procured and used after obtaining informed consent from all the participants. As a measure of prognosis, we analyzed the clinical data concerning DFS and OS. All recruited patients had been followed-up periodically until the due date. The mean follow-up duration was 29 months; the average survival time was 32 months (range, 13--52 months) for all patients.

In addition, peripheral blood mononuclear cells (PBMCs) from 115 benign pulmonary disease patients and 120 healthy subjects as normal controls were also included to examine the specificity of these markers. PBMCs were prepared as described below.

Informed consent was obtained from all individual participants included in the study. The research involved human participants. The study was approved by the Zhejiang Cancer Hospital Institutional Review Board (2012KYB035).

4.2. Sample Collection and Processing {#sec4dot2-ijms-17-01845}
-------------------------------------

Biopsies of NSCLC and paired PCHNTs were obtained from thoracic surgery patients. The peripheral blood samples were obtained from NSCLC patients. Peripheral blood samples from 115 benign pulmonary disease patients and 120 healthy subjects were provided by our hospital. Fresh tissue samples (\<300 mg) were immediately ground into powder in liquid nitrogen. Total RNA was extracted from these samples using 1 mL TRIzol (Invitrogen, Carlsbad, CA, USA) and stored at −80 °C until further use. The peripheral blood samples were collected and processed as described previously \[[@B37-ijms-17-01845]\]. In order to avoid contamination with skin epithelial cells, the first 2 mL blood was discarded while collecting the blood samples (7.5 mL). The PBMCs containing CTCs were prepared using Red Blood Cell Lysis Buffer (Solarbio, Beijing, China) and the blood samples were processed within 30 min. After centrifugation at 2000× *g* for 15 min, buffy coat was collected and washed once with phosphate buffered saline (PBS; containing 0.14 g/L KH~2~PO~4~, 9 g/L NaCl, 0.8 g/L Na~2~HPO~4~, pH 7.4). The cells were pelleted by centrifugation. Subsequently, the tumor cell enrichment using anti-EpCAM antibodies, MACS HEA MicroBeads^®^, density gradient centrifugation, and OncoQuick^®^ plus (Miltenyi Biotec Inc.,Bergisch Gladbach, Germany) was performed as described previously \[[@B17-ijms-17-01845],[@B38-ijms-17-01845],[@B39-ijms-17-01845],[@B40-ijms-17-01845]\]. For each cytometric enrichment procedure, 15 mL peripheral blood was used.

4.3. RNA Extraction and cDNA Synthesis {#sec4dot3-ijms-17-01845}
--------------------------------------

Total RNA of fresh tissue was isolated with TRIzol (Invitrogen, Carlsbad, CA, USA). The total RNA of PBMCs was extracted using the MiRNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. The concentration and purity of the total RNAs were assessed by Ultraviolet spectrophotometer, and the integrity of total RNAs was estimated by polyacrylamide electrophoresis (PAGE). cDNA synthesis was performed using PrimeScript^TM^ RT reagent Kit (Takara, Otsu, Japan) for tissue RNA and PrimeScript^TM^ miRNA cDNA Synthesis Kit (Takara, Otsu, Japan) for PBMCs RNA.

4.4. Real-Time RT-PCR {#sec4dot4-ijms-17-01845}
---------------------

The mRNA levels of the genes of interest were estimated by real-time RT-PCR on Applied Biosystems 7500 (Foster City, CA, USA) using SYBR^®^ Premix Ex Taq^TM^ II (Takara, Otsu, Japan). The sequences of primers were designed as described previously \[[@B17-ijms-17-01845],[@B18-ijms-17-01845]\]. To prepare an artificial CTC model as a positive control, a trace amount of A549 human lung adenocarcinoma cells was mixed with peripheral blood samples (five A549 cells in 7.5 mL peripheral blood). Then, the total RNA was extracted from the mixture and used as the positive control in real-time RT-PCR. The total amount of mRNA was normalized to *GAPDH*, and the relative mRNA expressions of the samples (tumor vs. PCHNTs, or paired PBMCs vs. positive control) were calculated by 2^−ΔΔ*C*t^. The differential expression of the samples may be defined as the upregulation when the cut-off value was set at 2-fold.

4.5. Statistical Analysis {#sec4dot5-ijms-17-01845}
-------------------------

The SPSS 17.0 statistical software package was used for all the statistical analyses. The correlation between the level of the above described four mRNAs and the clinicopathological characteristics was analyzed by Person's chi-square test or Fisher's exact test. The survival curves and univariate analysis were generated by the Kaplan-Meier method and log-rank test. Multivariate analysis was performed by the Cox regression model and Wald test. *p* \< 0.05 was considered statistically significant.

5. Conclusions {#sec5-ijms-17-01845}
==============

In present study, we selected *CK7*, *ELF3*, *EGFR* and *EphB4*, four epithelial origin markers, to evaluate their efficiency for detecting CTCs in NSCLC. The expression of *CK7*, *ELF3*, *EGFR* and *EphB4* in NSCLC tissues and para PMBCs were both upregulated significantly. ROC curve analysis indicated that these four genes have high sensitivity and specificity for detecting CTCs. Moreover, upregulation of four genes in PMBCs are associated with tumor progression closely. The patients with high expression of these genes in PMBCs have poor survival. We speculated that *CK7*, *ELF3*, *EGFR* and *EphB4* expression in PMBCs are appropriate markers for detecting CTCs and have potential in the evaluation of prognosis and monitoring of therapy in NSCLC.
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![Real-time reverse-transcription PCR (RT-PCR) analysis of marker gene expression in non-small cell lung carcinoma (NSCLC) tissues and paired peripheral blood mononuclear cell (PBMC) specimens. Total amount of mRNA was normalized to *GAPDH* and the relative mRNA expressions of the samples (tumor vs. para-cancerous histological normal tissues (PCHNTs), or paired PBMCs vs. positive control) were calculated using 2^−ΔΔ*C*t^ formula. (**A**) Tumor tissues vs. PCHNTs from 111 NSCLC patients. The mRNA expression of *CK7*, *ELF3*, *EGFR* and *EphB4* in lung cancer tissues were significantly higher than that in PCHNTs (all *p* \< 0.0001); T: Tumor tissues; P: PCHNTs; (**B**) PBMCs from 111 NSCLC patients vs. positive reference value (PRV). The mRNA expression of *CK7*, *ELF3*, *EGFR* and *EphB4* in PBMCs from NSCLC patients were significantly higher than that in healthy controls, respectively (all *p* \< 0.0001); P: PBMC; R: PRV. \*: *p* ˂ 0.0001.](ijms-17-01845-g001){#ijms-17-01845-f001}

![Receiver operating characteristics (ROC) curve analysis of the four mRNAs as a marker of circulating tumor cells (CTCs). The areas under the ROC curves are as follows: (**A**) *CK7*, 0.909 (0.853--0.965, 95.0% CI) with a sensitivity of 81.8% and a specificity of 100.0% for the discrimination between CTCs and the normal subjects; (**B**) *ELF3*, 0.917 (0.863--0.971, 95.0% CI) with a sensitivity of 83.3% and a specificity of 100.0% for the discrimination between CTCs and the normal subjects; (**C**) *EGFR*, 0.939 (0.893--0.986, 95.0% CI) with a sensitivity of 87.8% and a specificity of 100.0% for the discrimination between CTCs and the normal subjects; (**D**) *EphB4*, 0.894 (0.834--0.954, 95.0% CI) with a sensitivity of 78.8% and a specificity of 100.0% for the discrimination between CTCs and the normal subjects; (**E**) The area under the ROC curve was 0.848 (0.779--0.917, 95.0% CI), the sensitivity and specificity were 69.7% and 100%, respectively, when CTCs was detected using the combination of four markers; AUC: Area under curve.](ijms-17-01845-g002){#ijms-17-01845-f002}

![Kaplan-Meier survival analysis of DFS and OS based on the selected gene expression. Comparison of survival data from NSCLC patients positive or negative for epithelial cells in blood. Cum: Cumulative; (**A**) Kaplan-Meier curves of DFS in patients with NSCLC treated with curative surgery according to the expression of circulating *CK7*; (**B**) Kaplan-Meier curves of DFS in patients with NSCLC treated with curative surgery according to the expression of circulating *ELF3*; (**C**) Kaplan-Meier curves of DFS in patients with NSCLC treated with curative surgery according to the expression of circulating *EGFR*; (**D**) Kaplan-Meier curves of DFS in patients with NSCLC treated with curative surgery according to the expression of circulating *EphB4*; (**E**) Kaplan-Meier curves of OS in patients with NSCLC treated with curative surgery according to the expression of circulating *CK7*; (**F**) Kaplan-Meier curves of OS in patients with NSCLC treated with curative surgery according to the expression of circulating *ELF3*; (**G**) Kaplan-Meier curves of OS in patients with NSCLC treated with curative surgery according to the expression of circulating *EGFR*; (**H**) Kaplan-Meier curves of OS in patients with NSCLC treated with curative surgery according to the expression of circulating *EphB4*.](ijms-17-01845-g003){#ijms-17-01845-f003}
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Correlation of *CK7*, *ELF3*, *EGFR*, *EphB4* expression in tissues with NSCLC's clinicopathological characteristics.

  Clinicopathological Parameters   *N*             CK7             ELF3            EGFR                EphB4                                                                                   
  -------------------------------- --------------- --------------- --------------- ------------------- --------------- ------------------- --------------- ------------------- --------------- -------------------
  Gender                           Male            79              36.73 ± 19.44   0.608               36.64 ± 19.60   0.330               35.23 ± 20.76   0.590               32.98 ± 19.65   0.571
  Female                           32              34.60 ± 29.66   32.59 ± 20.20   32.84 ± 21.87       30.64 ± 19.76                                                                           
  Age (year)                       \<60            46              36.54 ± 18.05   0.852               36.24 ± 18.25   0.728               36.58 ± 20.62   0.393               34.41 ± 19.20   0.345
  ≥60                              65              35.82 ± 20.96   34.93 ± 20.89   33.10 ± 21.33       30.82 ± 19.92                                                                           
  Smoking history                  No              46              36.27 ± 21.05   0.947               34.45 ± 20.20   0.646               34.08 ± 20.61   0.847               32.84 ± 19.78   0.812
  Yes                              65              36.01 ± 18.90   36.21 ± 19.57   34.87 ± 21.45       31.93 ± 19.65                                                                           
  Lesion site                      Left lobe       50              34.45 ± 17.73   0.413               34.92 ± 19.38   0.790               33.65 ± 20.14   0.686               31.78 ± 18.85   0.797
  Right lobe                       61              37.49 ± 21.27   35.93 ± 20.22   35.28 ± 21.85       32.74 ± 20.37                                                                           
  Histopathological type           SCC             46              34.46 ± 18.00   0.460               35.14 ± 19.34   0.879               32.67 ± 19.35   0.423               31.03 ± 19.23   0.567
  ADC                              65              37.29 ± 20.92   35.72 ± 20.21   35.86 ± 22.17       33.21 ± 19.99                                                                           
  Tumor size                       ≤3 cm           24              37.47 ± 22.02   0.727               35.88 ± 20.95   0.938               36.82 ± 24.34   0.615               30.90 ± 18.19   0.653
  \>3 cm                           86              35.86 ± 19.25   35.52 ± 19.61   34.07 ± 20.18       32.94 ± 20.08                                                                           
  Differentiation                  Well/Moderate   86              34.84 ± 19.72   0.207               34.09 ± 19.47   0.173               33.23 ± 21.31   0.224               30.56 ± 19.60   0.082
  Poor                             25              40.51 ± 19.51   40.23 ± 20.42   39.05 ± 19.73       38.32 ± 18.81                                                                           
  T stage                          T2              94              35.55 ± 19.70   0.476               34.63 ± 19.68   0.289               33.33 ± 20.89   0.153               30.78 ± 19.18   0.053
  T3                               17              39.27 ± 20.16   40.18 ± 20.14   41.27 ± 21.08       40.77 ± 20.45                                                                           
  Lymph node status                N0              18              31.75 ± 13.75   0.188               30.02 ± 13.90   0.105               30.47 ± 15.85   0.275               28.47 ± 15.94   0.296
  N1--3                            93              36.96 ± 20.64   36.53 ± 20.60   35.33 ± 21.86       33.05 ± 20.24                                                                           
  Distant metastasis               M0              109             36.20 ± 19.85   0.735               35.56 ± 19.87   0.748               34.64 ± 21.12   0.721               32.39 ± 19.67   0.745
  M1                               2               31.40 ± 14.85   31.00 ± 16.69   29.25 ± 18.31       27.80 ± 22.49                                                                           
  Clinical stage                   I/II            56              28.13 ± 12.80   **1.06 × 10^−5^**   27.09 ± 13.95   **3.23 × 10^−6^**   25.14 ± 15.18   **7.62 × 10^−7^**   23.87 ± 14.95   **2.05 × 10^−6^**
  III/IV                           55              44.25 ± 22.18   44.01 ± 21.22   44.11 ± 21.91       40.90 ± 20.18                                                                           

SCC: squamous cell carcinoma; ADC: adenocarcinoma; Mean: mean value of relative expression; SD: standard deviation; Numbers in bold: *p* \< 0.05.
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###### 

Correlation of *CK7*, *ELF3*, *EGFR*, *EphB4* expression in PBMCs with NSCLC's clinicopathological characteristics.

  Clinicopathological Parameters   *N*             CK7          ELF3         EGFR         EphB4                                                                   
  -------------------------------- --------------- ------------ ------------ ------------ ------------ ------------ ------------------- ------------ ------------ -------
  Gender                           Male            79           40 (50.63)   0.432        41 (51.89)   0.605        41 (51.90)          0.014        39 (49.37)   0.699
  Female                           32              14 (43.75)   0.511        14 (43.75)   0.437        17 (55.13)   0.907               13 (40.63)   0.403        
  Age (year)                       \<60            46           17 (36.96)   4.299        20 (43.47)   1.158        22 (47.83)          0.617        19 (41.30)   0.969
  ≥60                              65              37 (56.92)   **0.038**    35 (53.84)   0.282        36 (55.38)   0.432               33 (50.77)   0.325        
  Smoking history                  No              46           26 (56.52)   1.949        26 (56.52)   1.528        28 (60.87)          2.338        24 (52.17)   0.895
  Yes                              65              28 (43.08)   0.163        29 (44.61)   0.216        30 (46.15)   0.126               28 (43.08)   0.344        
  Lesion site                      Left lobe       50           25 (50.00)   0.285        24 (48.00)   0.000        26 (52.00)          0.055        21 (42.00)   0.437
  Right lobe                       61              28 (45.90)   0.593        30 (49.18)   0.983        31 (50.82)   0.815               30 (49.18)   0.509        
  Histopathological type           SCC             46           19 (41.30)   1.696        20 (43.47)   1.158        22 (47.83)          0.617        16 (34.78)   4.592
  ADC                              65              35 (53.85)   0.193        35 (53.84)   0.282        36 (55.38)   0.432               36 (55.38)   **0.032**    
  Tumor size                       ≤3 cm           24           13 (54.17)   0.316        14 (58.33)   0.853        14 (58.33)          0.387        15 (62.50)   2.856
  \>3 cm                           86              41 (47.67)   0.574        41 (47.67)   0.356        44 (51.16)   0.534               37 (43.02)   0.091        
  Differentiation                  Well/Moderate   86           43 (50.00)   0.279        42 (48.83)   0.078        44 (51.16)          0.182        39 (45.35)   0.344
  Poor                             25              11 (44.00)   0.597        13 (52.00)   0.781        14 (56.00)   0.670               13 (52.00)   0.557        
  T stage                          T2              94           46 (48.94)   0.020        46 (48.93)   0.092        47 (50.00)          1.248        43 (45.74)   0.299
  T3                               17              8 (47.06)    0.887        9 (52.94)    0.761        11 (64.71)   0.264               9 (52.94)    0.584        
  Lymph node metastasis            N0              18           5 (27.78)    3.746        7 (38.88)    0.977        5 (27.78)           5.158        6 (33.33)    1.576
  N1--3                            93              48 (52.17)   0.053        47 (51.08)   0.323        52 (56.52)   **0.023**           45 (48.95)   0.209        
  Distant metastasis               M0              109          53 (48.62)   0.000        54 (49.54)   0.000        57 (52.29)          0.004        51 (46.79)   0.000
  M1                               2               1 (50.00)    1.000        1 (50.00)    1.000        1 (50.00)    0.949               1 (50.00)    1.000        
  Clinical stage                   I/II            56           20 (35.71)   7.569        20 (35.71)   8.654        19 (33.93)          15.210       19 (33.93)   7.574
  III/IV                           55              34 (61.82)   **0.006**    35 (63.63)   **0.003**    39 (70.91)   **9.62 × 10^−5^**   33 (60.00)   **0.006**    

SCC: squamous cell carcinoma; ADC: adenocarcinoma; up-regulated: the number of patients with gene upregulation; Numbers in bold: *p* \< 0.05.
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###### 

Univariate and multivariate analysis of survival in 110 patients with NSCLC according to clinicopathologic factors and circulating mRNA levels of *CK7*, *ELF3*, *EGFR* and *EphB4.*

  Clinicopathologic Factor   DFS             OS                                                                                                                                                                             
  -------------------------- --------------- --------------- --------------- -------- ---------------- --------- ----------------------- --------------- -------------- -------- --------------- -------- ----------------- ---------------
  Age                        \<60            45              21.69 ± 6.90    2.577    0.108            1.604     0.842--3.057            0.151           22.67 ± 6.43   2.608    0.106           2.184    0.894--5.337      0.086
  ≥60                        65              20.66 ± 7.75    24.15 ± 7.76                                                                                                                                                   
  Gender                     Male            78              19.92 ± 6.85    4.447    0.035            0.237     0.098--0.574            0.001           22.65 ± 5.95   8.597    0.003           0.120    0.026--0.553      0.006
  Female                     32              23.91 ± 8.02    25.72 ± 9.50                                                                                                                                                   
  Smoking                    No              45              21.33 ± 7.95    0.580    0.446            0.456     0.215--0.969            0.041           23.96 ± 8.00   0.707    0.401           0.578    0.220--1.519      0.266
  Yes                        65              20.91 ± 7.05    23.26 ± 6.74                                                                                                                                                   
  Lesion site                Left lobe       50              20.94 ± 7.79    0.003    0.957            0.873     0.476--1.601            0.660           24.26 ± 7.74   0.254    0.615           0.933    0.409--2.130      0.869
  Right lobe                 60              21.20 ± 7.12    22.95 ± 6.83                                                                                                                                                   
  Histopathological type     SCC             45              22.60 ± 7.85    2.286    0.131            1.374     0.654--2.888            0.401           24.76 ± 7.76   0.068    0.794           1.338    0.518--3.452      0.548
  ADC                        65              20.03 ± 6.94    22.71 ± 6.82                                                                                                                                                   
  Tumor size                 ≤3 cm           24              20.38 ± 6.28    0.833    0.361            0.894     0.421--1.897            0.769           24.12 ± 8.22   0.342    0.559           1.528    0.476--4.903      0.476
  \>3 cm                     85              21.34 ± 7.73    23.47 ± 7.00                                                                                                                                                   
  Differentiation            Well/Moderate   40              21.55 ± 6.92    0.016    0.898            0.685     0.326--1.439            0.318           23.80 ± 6.43   0.000    1.000           0.653    0.237--1.796      0.409
  Poor                       70              20.81 ± 7.70    23.40 ± 7.73                                                                                                                                                   
  T stage                    T2              93              20.92 ± 7.23    0.000    0.993            0.776     0.313--1.925            0.584           23.30 ± 6.92   0.269    0.604           0.410    0.120--1.407      0.156
  T3                         17              21.94 ± 8.45    24.88 ± 8.99                                                                                                                                                   
  Lymph node status          N0              18              19.28 ± 4.99    0.585    0.444            0.757     0.256--2.243            0.616           20.39 ± 3.27   0.455    0.500           0.497    0.133--1.859      0.299
  N1--3                      92              21.43 ± 7.76    24.16 ± 7.66                                                                                                                                                   
  Distant metastasis         M0              108             20.82 ± 7.09    2.229    0.135            0.000     0.000--9.74 × 10^233^   0.968           23.28 ± 6.82   0.417    0.519           1.451    0.139--15.122     0.756
  M1                         2               35.00 ± 14.14   38.00 ± 18.38                                                                                                                                                  
  Clinical stage             I/II            56              21.96 ± 6.89    5.723    0.017            1.878     0.903--3.903            0.091           23.29 ± 6.58   1.075    0.300           1.418    0.532--3.781      0.486
  III/IV                     54              20.17 ± 7.85    23.81 ± 7.95                                                                                                                                                   
  Circulating CK7 mRNA       \>2-fold        53              17.62 ± 7.95    82.565   1.02 × 10^−9^    132.315   10.691-1637.622         1.41 × 10^−4^   22.74 ± 9.00   36.447   1.57 × 10^−9^   91.148   3.863--2150.588   0.005
  Normal/low                 57              24.30 ± 5.11    24.30 ± 5.11                                                                                                                                                   
  Circulating ELF3 mRNA      \>2-fold        54              17.87 ± 8.00    77.808   1.13 × 10^−18^   119.681   10.024--1428.965        1.56 × 10^−4^   22.89 ± 8.91   34.479   4.31 × 10^−9^   84.458   3.655--1951.764   0.006
  Normal/low                 56              24.18 ± 5.19    24.18 ± 5.19                                                                                                                                                   
  Circulating EGFR mRNA      \>2-fold        57              18.39 ± 8.51    67.452   2.16 × 10^−16^   101.954   8.565--1213.683         2.53 × 10^−4^   23.14 ± 9.13   29.888   4.58 × 10^−8^   72.525   3.178--1655.090   0.007
  Normal/low                 53              23.98 ± 4.49    23.98 ± 4.49                                                                                                                                                   
  Circulating EphB4 mRNA     \>2-fold        52              17.69 ± 7.69    68.262   1.43 × 10^−16^   26.490    8.111--86.516           5.76 × 10^−8^   22.62 ± 8.88   30.619   3.14 × 10^−8^   19.010   4.487--80.547     6.40 × 10^−5^
  Normal/low                 58              24.12 ± 5.64    24.38 ± 5.34                                                                                                                                                   

SCC: squamous cell carcinoma; ADC: adenocarcinoma; DFS: disease free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; mo.: month; Normal: 0.5 ≤ 2^−ΔΔ*C*t^ ≤ 2; low: 2^−ΔΔ*C*t^ \< 0.5.
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